SCHEMBL13290653

SCHEMBL13290653

CC(C)NCC[Si](C)(C)Oc1ccc(C(C)(C)C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
ALDH1A1 P00352 4/20 0.39
TDP1 Q9NUW8 2/20 0.39
KDM4E B2RXH2 2/20 0.39
RAB9A P51151 4/20 0.38
LMNA P02545 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
POLB P06746 2/20 0.38
ATM Q13315 1/20 0.38
NPC1 O15118 4/20 0.38
NR1H4 Q96RI1 2/20 0.37
MAPK1 P28482 2/20 0.35
ALOX15 P16050 1/20 0.35
APEX1 P27695 1/20 0.35
RECQL P46063 1/20 0.35
HSD17B10 Q99714 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13290652 0.77 RAB9A (0.44) MEN1KMT2AALDH1A1TDP1KDM4E
SCHEMBL13290649 0.77 RAB9A (0.39) MEN1KMT2AALDH1A1KDM4ERAB9A
SCHEMBL13290647 0.76 RAB9A (0.43) MEN1KMT2AALDH1A1TDP1RAB9A
SCHEMBL18672993 0.74 KDM4E (0.58) MEN1KMT2AALDH1A1TDP1KDM4E
SCHEMBL13290628 0.73 KDM4E (0.64) MEN1KMT2AALDH1A1TDP1KDM4E
SCHEMBL105726 0.70 RAB9A (0.50) ALDH1A1TDP1KDM4ERAB9ALMNA
SCHEMBL13290633 0.70 MAPT (0.49) MEN1KMT2AALDH1A1TDP1KDM4E
SCHEMBL14094710 0.70 RAB9A (0.38) MEN1KMT2AALDH1A1TDP1KDM4E
SCHEMBL13290642 0.69 SMN1; SMN2 (0.43) MEN1KMT2AALDH1A1TDP1RAB9A
SCHEMBL13290650 0.69 CA1 (0.41) MEN1KMT2AALDH1A1TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7741289-B2 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2010-06-22 US disclosed
US-20080207585-A1 Substituted Azetidinone Compounds, Processes for Preparing the Same, Formulations and Uses Thereof SCHERING CORPORATION (US) 2008-08-28 US disclosed
US-7368563-B2 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2008-05-06 US disclosed
US-20070155675-A1 Substituted azetidinone compunds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2007-07-05 US disclosed
US-7235543-B2 Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof SCHERING CORPORATION (US) 2007-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207585-A1 Substituted Azetidinone Compounds, Processes for Preparing the Same, Formulations and Uses Thereof CYP46A1, NPC1L1, PCSK9 MEN1 253/4885KMT2A 3626/4885ALDH1A1 1219/4885
US-20070155675-A1 Substituted azetidinone compunds, processes for preparing the same, formulations and uses thereof APOB, NPC1L1, CYP46A1 MEN1 63/4885KMT2A 2537/4885ALDH1A1 2673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.